Advertisement
Advertisement
U.S. markets open in 1 hour 5 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Cytosorbents Corporation (CTSO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5100+0.1100 (+7.86%)
At close: 04:00PM EDT
1.5500 +0.04 (+2.65%)
Pre-Market: 08:01AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.4000
Open1.4400
Bid1.4600 x 1400
Ask1.6900 x 800
Day's Range1.4110 - 1.5800
52 Week Range1.1800 - 8.0200
Volume119,259
Avg. Volume138,937
Market Cap65.802M
Beta (5Y Monthly)0.42
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CTSO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cytosorbents Corporation
    Analyst Report: Illumina, Inc.Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
Advertisement
Advertisement